Beta2 Adrenergic Agonist Derivatives for Enhanced Therapeutic Efficacy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current β2 adrenergic receptor agonists have limitations in potency, selectivity, onset, and duration of action, which affects their therapeutic efficacy in treating pulmonary diseases, pre-term labor, glaucoma, and other disorders.
Innovation Solution
Development of novel β2 adrenergic receptor agonist compounds with specific structural formulas, including various substituents and functional groups, which are formulated into pharmaceutical compositions for improved therapeutic effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current β2 adrenergic receptor agonists are used, then therapeutic effects are achieved, but potency, selectivity, onset, and duration of action are less than desirable
Solution Approach 1:
The patent applies parameter changes by systematically modifying the chemical structure of β2 adrenergic receptor agonists through various substitutions at specific positions (R1-R6 groups) to optimize potency, selectivity, onset, and duration of action. This involves changing molecular parameters such as substituent types, positions, and configurations to achieve improved therapeutic properties while maintaining receptor affinity.
Solution Approach 2:
The patent employs local quality by introducing specific substituents at particular positions on the molecular framework (e.g., R2 being hydroxyl, alkoxy, or halo groups; R4 being specific aromatic substituents). Each position is optimized independently to enhance specific aspects of drug performance, such as selectivity for β2 receptors or duration of action, without compromising overall therapeutic efficacy.
2Reliability
If current β2 adrenergic receptor agonists are used, then therapeutic effects are achieved, but selectivity is less than desirable
Solution Approach 1:
The patent improves selectivity by changing molecular parameters including the introduction of specific aromatic substituents (R4 group), modification of amino group substitutions (R2, R5, R6), and optimization of the hydroxyl group configuration. These parameter changes enhance the drug's selective binding to β2 adrenergic receptors while reducing off-target effects.
Solution Approach 2:
The patent converts potential harmful non-selective binding into beneficial selective binding by strategically placing substituents that favor β2 receptor interaction. For example, specific R4 substituents and amino group modifications that would otherwise increase general adrenergic activity are instead configured to specifically enhance β2 selectivity, turning potential side effects into therapeutic advantages.
3Reliability
If current β2 adrenergic receptor agonists are used, then therapeutic effects are achieved, but onset and duration of action are less than desirable
Solution Approach 1:
The patent optimizes onset of action by changing molecular parameters such as the basicity of the amino groups (R2, R5, R6), the hydrophobicity of aromatic substituents (R1, R4), and the overall molecular flexibility. These parameter modifications facilitate faster receptor binding and activation, leading to improved onset of therapeutic effect.
Data Source
AI summary
This invention is directed to compounds of formula (I): to pharmaceutical compositions comprising them; to combination products comprising them; and to their use in therapy.